title: Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface.
abstract: The effect of human parathyroid hormone 1-34 (PTH) and zoledronic acid (ZA) alone or in combination on bone healing in osteoporotic settings was tested using implants inserted in tibiae of ovariectomized (OVX) rats. Combination therapy promoted bone healing more than each treatment alone 12 weeks after implant insertion.
  
  
  BACKGROUND
  PTH and ZA have been demonstrated to be effective on implant fixation. However, reports about the combined use of PTH and ZA for promotion of bone healing around implant in osteoporotic settings are still limited. This study aims to investigate effects of PTH+ZA on implant stabilization in OVX rats.
  
  
  METHODS
  Twelve weeks after bilateral ovariectomy, OVX rats randomly received implants without or with ZA (by immersion in 1 mg/ml ZA solution for 24 h). Subsequently, half of the animals from each group also received subcutaneous injections of PTH (60 μg/kg, three times a week) for 12 weeks. Thus, there were four groups: control, PTH, ZA, and PTH+ZA.
  
  
  RESULTS
  All treatments promoted bone healing around implant compared to control, but PTH+ZA treatment showed significantly stronger effects than PTH or ZA alone in histological, micro-CT, and biomechanical tests.
  
  
  CONCLUSIONS
  The results indicated the additive effects of PTH and ZA on implant fixation in OVX rats; it was suggested that the anabolic effect of PTH was potent and not blunted by ZA during bone healing around implant when used concurrently.
authors.affiliation: State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University, No 14, Section 3, Southern Renmin Road, Chengdu 610041, China.
authors.forename: Y F
authors.initials: YF
authors.lastname: Li
authors.forename: X D
authors.initials: XD
authors.lastname: Li
authors.forename: C Y
authors.initials: CY
authors.lastname: Bao
authors.forename: Q M
authors.initials: QM
authors.lastname: Chen
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: J
authors.initials: J
authors.lastname: Hu
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000494:pharmacology; D020099:Coated Materials, Biocompatible; D004164:Diphosphonates / Q000008:administration & dosage* / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D007093:Imidazoles / Q000008:administration & dosage* / Q000494:pharmacology; D020007:Implants, Experimental; D016348:Osseointegration / Q000187:drug effects*; D010024:Osteoporosis / Q000503:physiopathology*; D010052:Ovariectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D033081:Shear Strength / Q000187:drug effects; D013314:Stress, Mechanical; D019379:Teriparatide / Q000008:administration & dosage* / Q000494:pharmacology; D013977:Tibia / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery; D055114:X-Ray Microtomography; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D020099:Coated Materials, Biocompatible; D004164:Diphosphonates; D007093:Imidazoles; D019379:Teriparatide; D000077211:Zoledronic Acid